Prescription medicine
Dasiglucagon Brand names: Zegalogue
Dasiglucagon (Zegalogue) is a prescription medicine with an FDA approval on record since 2021. No generic is listed; pharmacies paid $493.36 per mL (Zegalogue 0.6 mg/0.6 mL autoinj) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the dasiglucagon FDA label on DailyMed (effective January 1, 2023, Novo Nordisk); the NDA 214231 record on Drugs@FDA; every dasiglucagon label on DailyMed.
Highlights of the record
FDA label of January 1, 2023; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageZEGALOGUE ® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Forms and strengths
- 0.6 mg/.6ml
Injection (solution).
On the market
- Earliest approval on file
- March 22, 2021 Zegalogue, Zealand Pharma; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- March 22, 2035 Zegalogue injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $493.36 per mL Zegalogue 0.6 mg/0.6 mL autoinj
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 52 through July 30, 2026
What is dasiglucagon used for?
From the label: indications and usageZEGALOGUE ® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. ZEGALOGUE is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
FDA pharmacologic class: Antihypoglycemic Agent.
Source: FDA drug label (Zegalogue), NDA214231 (Zealand Pharma), as published by Novo Nordisk, effective January 1, 2023 (SPL set 14704879-872c-4967-8779-04a3bbdfb4e6), via openFDA; the full label on DailyMed
Is there a generic for dasiglucagon (Zegalogue)?
No generic dasiglucagon is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 2 patents for Zegalogue injection: the compound patent runs to March 22, 2035. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2021 earliest approval on file
- 2035 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for dasiglucagon (Zegalogue)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $493.36 per mL (Zegalogue 0.6 mg/0.6 mL autoinj), about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Zegalogue 0.6 mg/0.6 mL autoinj (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Zegalogue 0.6 mg/0.6 mL autoinj | Brand | $493.36 per mL | $296.02 per autoinj | no change |
| Zegalogue 0.6 mg/0.6 mL syring | Brand | $494.54 per mL | n/a | -0.2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the dasiglucagon label say about other medicines?
The dasiglucagon label names 4 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Glucagon | warnings and precautions | Hypersensitivity and Allergic Reactions: Allergic reactions have been reported with glucagon products and may include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. |
| Indomethacin | drug interactions | Clinical Impact: In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may even produce hypoglycemia. |
| Phentolamine | warnings and precautions | If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure. |
| Warfarin | drug interactions | Clinical Impact: ZEGALOGUE may increase the anticoagulant effect of warfarin. Beta-blockers: Patients taking beta-blockers may have a transient increase in pulse and blood pressure. Indomethacin: In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may produce hypoglycemia. … |
Source: FDA drug label (Zegalogue), NDA214231 (Zealand Pharma), as published by Novo Nordisk, effective January 1, 2023 (SPL set 14704879-872c-4967-8779-04a3bbdfb4e6), via openFDA; the full label on DailyMed
What do FAERS reports show for dasiglucagon?
The FDA Adverse Event Reporting System holds 52 reports that list dasiglucagon among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 15 are coded as a death and 8 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other antihypoglycemic agents
- the pharmacologic class, with prices and generics
- Dasiglucagon side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other